Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.79 -0.04 (-0.28%)

Delayed Quote Updated: 3:19 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results

November 03, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Earnings Preview For Aurinia Pharmaceuticals ↗

November 02, 2022

Aurinia Pharmaceuticals (NASDAQ:AUPH) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022

October 28, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022

October 27, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday ↗

October 24, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.

Via Benzinga

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022

September 20, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

September 19, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

NASDAQ: AUPH Long Term Investor Alert: Investigation of Potential Wrongdoing at Aurinia Pharmaceuticals Inc. ↗

August 15, 2022

San Diego, CA -- (SBWIRE) -- 08/15/2022 -- Certain directors of Aurinia Pharmaceuticals Inc. are under investigation over possible breaches of fiduciary duties.

Via SBWire

Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock ↗

August 09, 2022

Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.

Via Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results

August 04, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

July 27, 2022

Wednesday saw 83 companies set new 52-week lows.

Via Benzinga

Why Aurinia Pharmaceuticals Stock Is Plunging ↗

July 26, 2022

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading lower Tuesday after the company received a notice regarding the U.S. Patent Office Patent Trial and Appeal Board's decision to institute...

Via Benzinga

Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday ↗

July 27, 2022

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.

Via Benzinga

Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review

July 26, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022

July 25, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe

July 22, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread ↗

July 15, 2022

The company just hired three new executives, likely putting a buyout in the rearview.

Via Investor's Business Daily

Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance

July 14, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday ↗

July 18, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering...

Via Benzinga

Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Aurinia Pharmaceuticals Inc. (AUPH) Investors of Class Action and Last Day to Actively Participate

June 13, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session ↗

July 15, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) shares jumped 180.9% to $6.19. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on Wednesday.

Via Benzinga

AURINIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

June 11, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

AUPH FINAL DEADLINE TUESDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 14 Deadline in Securities Class Action - AUPH

June 11, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

NASDAQ:AUPH Investor Notice: Deadline on June 14, 2022 in Lawsuit Against Aurinia Pharmaceuticals Inc. ↗

June 08, 2022

San Diego, CA -- (SBWIRE) -- 06/08/2022 -- The Shareholders Foundation announced that a deadline is coming up on June 14, 2022 in the lawsuit filed for certain investors of Aurinia Pharmaceuticals Inc....

Via SBWire

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

June 03, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More ↗

May 30, 2022

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.